Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated…
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated…
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk…
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk…
Highlights Include Multiple Presentations Addressing Safety and Efficacy of Trudhesa SEATTLE, April 11, 2023 (GLOBE…
Highlights Include Multiple Presentations Addressing Safety and Efficacy of Trudhesa SEATTLE, April 11, 2023 (GLOBE…
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential…
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential…
SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q),…
SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q),…
PharmAla contracted Filament subsidiary Psilo Scientific to manufacture the drug product for distribution to clinical…
PharmAla contracted Filament subsidiary Psilo Scientific to manufacture the drug product for distribution to clinical…
Seattle, April 11, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing…